ArticleFrontiers in oncology2024

Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma.

Lei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.